Loading
The purpose-built tracer for sentinel lymph node mapping in breast cancer, melanoma and oral cancer, replacing off-label sulfur colloid.
Technetium-99m tilmanocept is a mannosylated dextran labelled with technetium-99m that binds CD206, the mannose receptor on macrophages in lymph nodes. Because it is small it drains rapidly from the injection site, and because it binds a receptor it stays in the sentinel node rather than passing through to second-echelon nodes, which simplifies surgery. It was the first agent purpose-built for sentinel lymph node mapping, replacing off-label sulfur colloid. The FDA approved it in March 2013 for breast cancer and melanoma, in 2014 for sentinel node localisation in oral cavity squamous cell carcinoma, where mapping showed 97.8% sensitivity, and extended it to children in 2017; the EU approved it in 2014. It is detected with a handheld gamma counter in theatre. Tilmanocept finds the first node a cancer would spread to so that only that node needs removal.
Mannosylated dextran that binds CD206 (mannose receptor) on macrophages in sentinel nodes, giving rapid uptake and low pass-through to second-echelon nodes.
1.Technetium-99m tilmanocept binds its target on the cancer cell or is taken up by it.
Radiopharmaceutical for sentinel lymph node mapping, billed with the nuclear medicine procedure under Part B; when used in the operating room it is bundled into the surgical payment.
Covered as part of the sentinel node procedure for breast cancer, melanoma and oral cancer; no separate authorisation.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B) · Medicare.gov: Diagnostic non-laboratory tests (imaging). Not medical or financial advice; verify with your plan.
Sources: NICE search: technetium-99m tilmanocept. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| US | 2013 | Lymphatic mapping with a handheld gamma counter in breast cancer and melanoma |
| US | 2014 | Sentinel lymph node localisation in oral cavity squamous cell carcinoma |
| EU | 2014 | Sentinel node imaging in breast cancer, melanoma, oral SCC |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Technetium-99m tilmanocept" OR ABSTRACT:"Technetium-99m tilmanocept" OR TITLE:"Lymphoseek" OR ABSTRACT:"Lymphoseek") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Technetium-99m tilmanocept, not a curated reading list.
Shares HR-positive / HER2-negative breast cancer and the tag diagnostic.
Shares HR-positive / HER2-negative breast cancer and the tag diagnostic.
Shares Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial, Sentinel lymph node biopsy, Melanoma, HR-positive / HER2-negative breast cancer.
Shares Sentinel node biopsy, Sentinel lymph node biopsy, HR-positive / HER2-negative breast cancer.
Shares Sentinel node biopsy, Sentinel lymph node biopsy, HR-positive / HER2-negative breast cancer.
Shares Sentinel node biopsy, Sentinel lymph node biopsy, HR-positive / HER2-negative breast cancer.
Shares Sentinel node biopsy, Sentinel lymph node biopsy, HR-positive / HER2-negative breast cancer.
Shares Sentinel node biopsy, Sentinel lymph node biopsy, HR-positive / HER2-negative breast cancer.